Risk of infection in patients with lymphoma receiving Rituximab: systematic review and meta-analysis Full Text
BMC Medicine, 04/15/2011
Evidence Based Medicine
Lanini S et al. – Rituximab (R)–chemotherapy (C) is superior to standard C in terms of overall response and it does not increase the overall incidence of severe infection. However data on special groups of patients are lacking.